Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Alfa
Study Identifier:
D8590C00002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1850
- Drug: Placebo
Date
Jan 2024 - Jul 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 130 Years
Requirements Information
Sex
Female & Male
Age
12 - 130 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1850
- Drug: Placebo
Date
Jan 2024 - Jul 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 12 - 130 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to assess the efficacy of ALXN1850 versus
placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Trial Locations
Location
Status
Location
Research Site
Seoul, Unmapped, 07061
Status
Active, not recruiting
Location
Research Site
Minato-ku, Japan, 105-8470
Status
Withdrawn
Location
Research Site
Sapporo-shi, Japan, 060-8648
Status
Active, not recruiting
Location
Research Site
Taipei, Unmapped, 100
Status
Active, not recruiting
Location
Research Site
Westmead, Unmapped, 2145
Status
Withdrawn
Location
Research Site
Parkville, Unmapped, 3052
Status
Terminated